reports
Wereldhave Nv: 2 directors
Two Directors at Wereldhave Nv bought 50,425 shares at 13.100EUR. The significance rating of the trade was 89/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Kuros Biosciences Ag: 1 director
A director at Kuros Biosciences Ag sold 7,181 shares at 6.955CHF and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Compagnie Financière Tradition S.A.: 1 director
A director at Compagnie Financière Tradition S.A. sold 184 shares at 144.000CHF and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Pitney Bowes Declares Common Stock Dividend
STAMFORD, Conn.--(BUSINESS WIRE)-- Pitney Bowes Inc. (NYSE:PBI), a global shipping and mailing company that provides technology, logistics, and financial services, today announced that its Board of Directors has declared a quarterly cash dividend on the company’s common stock of $0.05 per share. The dividend will be paid on June 7, 2024 to stockholders of record on May 23, 2024. About Pitney Bowes Pitney Bowes (NYSE:PBI) is a global shipping and mailing company that provides technology, logistics, and financial services to more than 90 percent of the Fortune 500. Small business, retail, en...
EQS-News: MEDICLIN steigert Konzernumsatz und Betriebsergebnis im erst...
EQS-News: MEDICLIN AG / Schlagwort(e): Quartals-/Zwischenmitteilung MEDICLIN steigert Konzernumsatz und Betriebsergebnis im ersten Quartal 2024 02.05.2024 / 13:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Offenburg, 2. Mai 2024 MEDICLIN steigert Konzernumsatz und Betriebsergebnis im ersten Quartal 2024 MEDICLIN steigert seinen Konzernumsatz für das erste Quartal 2024 um 4,9 % auf 185,4 Mio. Euro Konzern-EBIT mit 4,1 Mio. Euro deutlich höher als im Vorjahreszeitraum (-1,7 Mio. Euro) Auslastung mit 85,1 % gegenüber Vorjahr ge...
EQS-News: MEDICLIN increases consolidated sales and operating result i...
EQS-News: MEDICLIN AG / Key word(s): Quarterly / Interim Statement MEDICLIN increases consolidated sales and operating result in the first quarter of 2024 02.05.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Offenburg, 2 May 2024 MEDICLIN increases consolidated sales and operating result in the first quarter of 2024 MEDICLIN increases its consolidated sales for the first quarter of 2024 by 4.9% to EUR 185.4 million Group EBIT of EUR 4.1 million significantly higher than in the same period of the previous year (EUR -1.7 m...
Kimco Realty® Announces First Quarter 2024 Results
Kimco Realty® Announces First Quarter 2024 Results – Strong Growth and Leasing Activity – – Successful Execution on RPT Realty Acquisition – – Board Declares Quarterly Dividend – – Updates 2024 Outlook – JERICHO, N.Y., May 02, 2024 (GLOBE NEWSWIRE) -- Kimco Realty® (NYSE: KIM), a real estate investment trust (REIT) and leading owner and operator of high-quality, open-air, grocery-anchored shopping centers and mixed-use properties in the United States, today reported results for the first quarter ended March 31, 2024. For the three months ended March 31, 2024 and 2023, Kimco Realty’s n...
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent ...
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June – - Randomized, controlled Phase 1B dose-expansion cohort in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients expected to initiate enrollment in the second quarter of 2024 – - Presented preclinical data at the 2024 Americ...
Appian Announces First Quarter 2024 Financial Results
Appian Announces First Quarter 2024 Financial Results First quarter cloud subscription revenue increased 24% year-over-year to $86.6 million MCLEAN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the first quarter ended March 31, 2024. “Appian continues to push technological boundaries in our industry, from AI-backed services to process mining. Organizations globally are recognizing the power and simplicity of the Appian Platform,” said Matt Calkins, CEO & Founder. First Quarter 2024 Financial Highlights: Revenue: Cloud subscription ...
Gilat to Participate in the 19th Annual Needham Technology, Media & Co...
Gilat to Participate in the 19th Annual Needham Technology, Media & Consumer Conference on May 15, 2024 PETAH TIKVA, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced management’s participation in the 19th Annual Needham Technology, Media and Consumer Conference at the Westin Grand Central Hotel in New York City. Mr. Adi Sfadia, the Company’s CEO, and Mr. Gil Benyamini, the Company’s CFO, will be available for one-on-one meetings with investors at the...
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Fina...
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocure’s discretion and subject to certain milestones, through March 31, 2026. The proceeds will be used ...
Sotera Health Reports First-Quarter 2024 Results
Sotera Health Reports First-Quarter 2024 Results Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023Q1 2024 net income of $6 million or $0.02 per diluted share, compared to net income of $3 million or $0.01 per diluted share in Q1 2023Q1 2024 Adjusted EBITDA(1) increased 13.7% to $112 million, compared to Q1 2023Q1 2024 Adjusted EPS(1) of $0.13 compared to Adjusted EPS of $0.13 in Q1 2023Company reaffirms 2024 outlook CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of missi...
Arvinas to Present at Upcoming Investor Conferences
Arvinas to Present at Upcoming Investor Conferences NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: BofA Securities 2024 Healthcare Conference on Tuesday, May 14 at 3:00 p.m. PT in Las Vegas. Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presen...
Kymera Therapeutics Announces First Quarter 2024 Financial Results and...
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively Well-capitalized with $745 million in cash as of March 31, 2024, and runway into ...
Alta Equipment Group Announces Common Stock Dividend
Alta Equipment Group Announces Common Stock Dividend LIVONIA, Mich., May 02, 2024 (GLOBE NEWSWIRE) -- Alta Equipment Group Inc. (NYSE: ALTG) (“Alta” or "the Company"), a leading provider of premium material handling, construction and environmental processing equipment and related services, today announced that its Board of Directors approved the quarterly dividend on its common stock in the amount of $0.057 per share. The dividend payment date is May 31, 2024, to shareholders of record at the close of business on May 15, 2024. About Alta Equipment Group Inc.Alta owns and operates one o...
Agios Reports Business Highlights and First Quarter 2024 Financial Res...
Agios Reports Business Highlights and First Quarter 2024 Financial Results – Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia in January – – Phase 3 Readouts from Mitapivat RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $...
Lee Enterprises reports second quarter Adjusted EBITDA growth and stro...
Lee Enterprises reports second quarter Adjusted EBITDA growth and strong digital growth Adjusted EBITDA(1) growth of 5% YOYDigital-only subscription revenue increased 48%(2) with subscriptions up 25%Total Digital Revenue(3) of $71M represented 48% of total revenue DAVENPORT, Iowa, May 02, 2024 (GLOBE NEWSWIRE) -- Lee Enterprises, Incorporated (NASDAQ: LEE), a digital-first subscription platform providing high quality, trusted, local news, information and a major platform for advertising in 73 markets, today reported preliminary second quarter fiscal 2024 financial results(4) for the peri...
Colliers Reports First Quarter Results
Colliers Reports First Quarter Results Continued growth and resiliency from highly diversified recurring services First quarter operating highlights: Three months ended March 31(in millions of US$, except EPS) 2024 2023 Revenues$1,002.0 $965.9 Adjusted EBITDA (note 1) 108.7 104.6 Adjusted EPS (note 2) 0.77 0.86 GAAP operating earnings 43.3 22.1 GAAP diluted net earnings (loss) per share 0.26 (0.47) TORONTO, May 02, 2024 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI) (“Colliers” or the “Company”) today announced operating and financial resul...
DAVIDsTEA Reports Fourth Quarter and Full Year Fiscal 2023 Financial R...
DAVIDsTEA Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results Fiscal 2023 Sales of $60.6 millionNet loss of $13.8 millionAdjusted EBITDA of negative $5.4 millionCash position of $12.6 millionCompany enters into non-binding term sheet for revolving line of credit of up to $12.0 million Q4 Fiscal 2023 Sales of $24.4 millionNet loss of $3.9 millionAdjusted EBITDA of $0.5 million MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- DAVIDsTEA Inc. (TSX-Venture: DTEA) (“DAVIDsTEA” or the “Company”), a leading tea merchant in North America, announced today its fo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.